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IntroductIon
Central obesity is an integral component of the metabolic syn-
drome, and it is associated with increased risk of type 2 diabe-
tes and cardiovascular disease. In addition, the risks of type 2 
diabetes and cardiovascular disease are particularly high among 
patients with metabolic syndrome and high levels of certain 
inflammatory makers such as C-reactive protein (CRP) (1,2) and 
low levels of the anti-inflammatory protein adiponectin (3,4).
Visceral fat promotes inflammation through increased secre-
tion of tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6) (5). These inflammatory cytokines activate the oxidant-
stress response transcription factor nuclear factor-κB (NF-κB) 
that is present in various cell types (6). In hepatocytes, these 
inflammatory cytokines modulate synthesis of acute phase 
proteins such as CRP and fibrinogen.
Adiponectin is an adipocyte-derived plasma protein that 
suppresses TNF-α induced activation of NF-κB in human aor-
tic endothelial cells and aortic smooth muscle cells through 
inhibition of IκB phosphorylation (7,8). Anti-inflammatory 
effects of adiponectin include inhibited endothelial adhesion 
molecule expression, reduced monocyte adhesion, inhibited 
macrophage-induced cytokine production (9), and reduced 
CRP expression in human adipose tissue (10).
This study sought to demonstrate whether the fenofibrate-
mediated increases in adiponectin levels are associated with 
reduced circulating levels of inflammatory mediators. In 
addition, we evaluated whether increases in adiponectin are 
associated with reductions in ex vivo inflammatory cytokine 
production in whole blood specimens.
Methods And Procedures
selection of patients
The study population consisted of 59 subjects with the metabolic syn-
drome as previously described (11). Four subjects did not complete the 
protocol because of withdrawal of consent (n = 2), relocation (n  = 1), 
or gastrointestinal intolerance (n = 1). Therefore, 55 subjects (25 inter-
vention subjects and 30 control subjects) completed the study and 
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were included in the final analyses. Male and postmenopausal females 
>18 years of age with fasting triglycerides ≥1.7 and <6.8 mmol/l were 
included in the study. Subjects were required to have ≥2 of the fol-
lowing Adult Treatment Panel III (12) criteria of the metabolic syn-
drome: abdominal obesity (waist circumference >89 cm in females and 
>102 cm in males); low high-density lipoprotein cholesterol (HDL-C) 
(<1.3 mmol/l in women and <1.0 mmol/l in men); hypertension (systo-
lic blood pressure ≥130 or diastolic blood pressure ≥85 mm Hg) or 
current drug therapy for hypertension; and impaired fasting glucose 
≥6.1 mmol/l and <7.0 mmol/l. Exclusion criteria included BMI >40 kg/
m2; type 1 or type 2 diabetes; use of lipid-lowering therapies, aspirin 
>81 mg daily, regular use of nonsteroidal anti-inflammatory agents or 
cyclooxygenase-2 inhibitors, corticosteroids (oral and inhaled), anti-
oxidants (including multivitamins), herbal or fiber supplements; recent 
changes in type or formulation of hormone replacement therapy (in 
the last 6 months); alcohol intake more than three drinks per day; 
untreated hypothyroidism or recent change (within 2 months) of thy-
roid replacement therapy; and cigarette smoking (current or within the 
past 6 months).
The Institutional Review Board approved the protocol of this study. 
All subjects gave written informed consent before participating in this 
research trial.
study design
A registered dietitian counseled subjects on the American Heart 
Association Step 2 diet, and they were instructed to maintain the diet 
throughout the study. The dietitian contacted subjects twice during 
the 6-week dietary lead-in period to obtain 24-h diet recalls. The food 
recalls were analyzed for fat, calories, fiber, and alcohol intake using the 
Minnesota Nutrition Data System, version 2.93. At the end of a 6-week 
run-in period, fasting lipids and glucose were measured to determine 
study eligibility, and within 1 week subjects returned for randomization. 
Subjects were randomized to fenofibrate 160 mg/day (TriCor, Abbott 
Laboratories, Abbott Park, IL) or placebo for the next 3 months. Fasting 
blood specimens were obtained after a 12-h fast at both randomization 
and study completion (month 3).
Laboratory studies
Plasma lipids and serum chemistries were analyzed by standard tech-
niques. Lipoprotein subclass profiles were measured with an automated 
nuclear magnetic resonance spectroscopic assay using a modification of 
the method described previously (LipoScience, Raleigh, NC) (13).
Chemokines, cytokines, and adhesion molecules were measured in 
duplicate on plasma samples using monoclonal antibody-based multi-
analyte bead immunoassays (Luminex, Linco Research, St Charles, MO). 
Cytokine and chemokine production was measured on lithium-heparin 
whole blood specimens that were stimulated with lipopolysaccharide 
(LPS) (100 ng/ml) for 6 h at 37 °C.
Total plasma adiponectin concentration was measured in duplicate 
and assayed by an ELISA method (Human Adiponectin/Acrp30 Immu-
noassay, Quantikine, R&D systems, Minneapolis, MN). The interassay 
coefficient of variation for this test was <7%. CRP was measured with a 
high-sensitivity enzyme-linked immunosorbent assay (Life Diagnostics, 
West Chester, PA). Fibrinogen was analyzed and measured in duplicate 
by a modified method of Clauss (14). Interassay coefficients of variation 
were <5% for CRP and fibrinogen, and <12% for the other inflammatory 
markers.
statistical analyses
Subject demographic characteristics, as well as fasting lipids and lipo-
proteins are reported as means ± s.d. (Table 1). Person-specific percent 
changes over the 3-month therapy period in weight, waist circumfer-
ence, fasting lipids, and lipoproteins, as well as characteristics of inflam-
matory markers and their respective percent changes are reported as 
medians and interquartile ranges (IQRs). The IQR gives the 25th and 
75th percentile. Wilcoxon rank sum test and Fisher’s exact test were 





(n = 25) P
Clinical
 Age, years 55.22 ± 10.01 51.54 ± 9.66 0.088
 Sex, male/female 22/8 19/6 0.99
 BMI, kg/m2 33.29 ± 3.50 32.19 ± 4.02 0.25
  Waist circumference, 
cm
109.5 ± 8.9 108.9 ± 8.4 0.63
  Systolic blood pressure, 
mm Hg
133.48 ± 13.46 131.84 ± 12.60 0.71
  Diastolic blood 
pressure, mm Hg
84.97 ± 7.89 82.48 ± 7.81 0.39
 Fasting glucose, mmol/l 4.74 ± 0.84 4.70 ± 0.91 0.88
 Fasting insulin, µU/l 6.91 ± 5.06 6.88 ± 4.38 0.79
 HOMA index 1.48 ± 1.19 1.49 ± 1.10 0.92
Fasting chemical lipids
 Triglycerides, mmol/l 3.10 ± 1.05 3.20 ± 0.98 0.65
 Total cholesterol, mmol/l 5.37 ± 1.19 5.54 ± 1.20 0.51
 LDL-C, mmol/l 3.46 ± 1.11 3.53 ± 1.02 0.64
 HDL-C, mmol/l 0.88 ± 0.29 0.82 ± 0.23 0.44
 Non-HDL-C, mmol/l 4.49 ± 1.19 4.72 ± 1.16 0.35
NMR-derived fasting lipoprotein subclasses
  Total VLDL particle, 
nmol/l
129.58 ± 51.89 154.97 ± 60.06 0.061
  Large VLDL particle, 
nmol/l
12.94 ± 7.77 10.69 ± 7.56 0.32
  Medium VLDL particle, 
nmol/l
75.84 ± 41.83 85.21 ± 41.97 0.37
  Small VLDL particle, 
nmol/l
40.80 ± 30.16 59.07 ± 37.05 0.041
  Total LDL particle, 
nmol/l
1,797.58 ± 588.71 1,813.61 ± 502.68 0.71
  Large LDL particle, 
nmol/l
269.57 ± 239.61 284.56 ± 243.36 0.83
  Small LDL particles, 
nmol/l
1,475.04 ± 561.64 1,476.19 ± 473.23 0.99
 OH-FA, μmol/l 1.15 ± 0.34 1.15 ± 0.34 0.74
Characteristics of the metabolic syndrome
  High triglycerides, Yes/
No
100/0 100/0 —
 Low HDL-C,a Yes/No 23/7 19/6 0.99
 Central obesity,b Yes/No 29/1 23/2 0.49
 Elevated blood pressure 20/10 13/12 0.29
 Elevated fasting glucose 1/29 1/24 0.99
Data are given as means ± s.d. for continuous variables, frequencies for 
dichotomous variables. HOMA index was calculated according to the formula: 
fasting glucose (mmol/l) × insulin (mU/ml)/22.5.
HDL-C, high-density lipoprotein cholesterol; HOMA, homeostasis model assess-
ment; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; 
NMR, nuclear magnetic resonance; OH-FA, monohydroxy fatty acids; VLDL, very 
low-density lipoprotein.
aLow HDL cholesterol levels were defined as <1.0 mmol/l in men and <1.3 mmol/l 
in women. bCentral obesity was defined as a waist circumference >89 cm in 
women and >102 cm in men.
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used to compare continuous and dichotomous variables, respectively, 
between treatment groups. Percent change over the treatment phase 
between adiponectin and inflammatory markers were correlated using 
Spearman’s correlations, and both treatment groups were combined for 
these correlations. Multivariate Spearman’s correlations were calculated 
as partial correlations on residual ranks. All statistical analyses were 
performed with SAS package 2003 (SAS Institute, Cary, NC).
This study was an investigator-initiated clinical trial, and was 
 conceived, managed, and analyzed independently of the sponsor. Stat-
isticians (Alfred W. Rademaker and Irene B. Helenowski) employed 
by Northwestern University performed the statistical analysis based 
on specific requests of the investigators.
resuLts
The baseline characteristics of the study populations are 
described in Table 1. This study included predominantly mid-
dle-aged men with central obesity, high fasting triglycerides, 
low levels of HDL-C, and hypertension. Only two subjects had 
fasting glucose levels ≥6.1 mmol/l. Treatment groups were well 
balanced with regards to baseline demographics and labora-
tory values, in particular there were no differences between 
treatment groups in baseline blood glucose (P = 0.88), insulin 
concentration (P = 0.79) or HOMA index (P = 0.92).
Aspirin (75–81 mg daily) was used in 50% of placebo-treated 
subjects and 32% of fenofibrate-assigned subjects (P = 0.56). 
Subjects did not change their intake of dietary fats and calo-
ries during the study, and they demonstrated high adherence 
to study medications, with 97.6% of placebo-treated subjects 
and 97.1% of fenofibrate-treated subjects returning the cor-
rect number of tablets. Weight remained stable in the placebo 
group (median (IQR), 101.8 kg (96.3, 114.1) vs. 103.2 kg (93.2, 
115.5)), and the fenofibrate-treatment group (median (IQR), 
105.0 kg (87.3, 113.2) vs. 104.5 kg (86.4, 112.7)); P = 0.056). 
There were no changes in waist circumference between pla-
cebo (median (IQR) 46.3 in (41.0, 46.0) vs. 44.0 (40.5, 46.0) 
and fenofibrate-treatment group (median (IQR), 43.0 in (41.8, 
44.3) vs. 43.0 (41.0, 45.0); P = 0.10).
Adiponectin and fenofibrate
In the fenofibrate group, median adiponectin levels increased 
by 0.40 mg/l from 4.10 to 4.50 mg/l (an increase of 7.7%); in the 
placebo group, median adiponectin levels did not change (P = 
0.0005 comparing change between groups) (Table 2).
Proinflammatory markers and fenofibrate
Subjects assigned to fenofibrate therapy had greater reductions 
than the placebo group in systemic concentrations of vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1) and CRP (Table 2). LPS-stimulated 
production of monocyte chemotactic protein-1 (MCP-1), 
macrophage inflammatory protein-1α (MIP-1α), and IL-1β 
were significantly reduced more by fenofibrate therapy than by 
placebo (Table 3).
correlations between adiponectin and inflammatory 
markers
In multivariate models that included age, gender, and on-trial 
weight changes, we demonstrate inverse correlations between 
changes in plasma adiponectin levels and changes in VCAM-1 
(r = −0.54, P < 0.0001), ICAM-1 (r = −0.57, P < 0.0001), and 
table 2 effects of fenofibrate on fasting circulating inflammatory proteins
Placebo Fenofibrate
P valueBaseline Treatment % Change Baseline Treatment % Change
Adiponectin, mg/l 4.50 (3.90, 5.40) 4.50 (4.10, 5.40) +1.8 (−1.6, 2.9) 4.10 (3.70, 4.90) 4.50 (4.10, 5.30) +7.7 (2.27, 14.63) 0.0005








−10.9 (−14.6, −8.2) 0.0005








−14.7 (−22.3, −10.1) <0.0001
CRP, mg/l 2.4 (2.0, 3.2) 2.2 (1.6, 2.7) −6.5 (−24.5, 1.7) 2.6 (1.4, 3.1) 1.9 (1.1, 2.6) −24.5 (−31.9, −9.8) 0.02
Fibrinogen, g/l 3.54 (3.13, 3.84) 3.52 (3.1 3.85) 3.1 (−7.0, 12.2) 3.35 (31.0, 3.57) 3.05 (2.67. 3.59) −5.4 (−17.0, 7.2) 0.054
Data represents LPS-stimulated (100 ng/ml) whole blood production of inflammatory cytokines.
Values are expressed as medians and interquartile ranges (25th, 75th percentile).
table 3 effects of fenofibate on lipopolysaccharide-stimulated cytokine production
Placebo Fenofibrate
P valueBaseline Treatment % Change Baseline Treatment % Change








−3.4 (−5.0, −0.4) 0.01








−3.5 (−4.6, −0.9) 0.01








−2.5 (−4.7, 0.3) 0.044
Values are expressed as medians and interquartile ranges (25th, 75th percentile).
IL-1β, interleukin-1β; MCP-1, monocyte chemotactic protein-1; MIP-1α, macrophage inflammatory protein-1α.
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CRP (r = −0.40, P = 0.0041) (Table 4). There were nonsignifi-
cant associations between adiponectin and plasma fibrinogen 
(r = −0.26, P = 0.078). There were inverse correlations between 
plasma adiponectin and LPS-stimulated whole blood produc-
tion of MCP-1 (r = −0.46, P = 0.0010), MIP-1α (r = −0.45, P = 
0.001), and IL-1β (r = −0.44, P = 0.0016) in fenofibrate-treated 
subjects (Figure 1). Although, there was a nonsignificant reduc-
tion in TNF-α production in the fenofibrate group, TNF-α 
production was inversely correlated with adiponectin levels 
(r = −0.30, P = 0.035). No such correlations were observed in 
patients treated with placebo.
dIscussIon
This study demonstrates that short-term (12 week) therapy with 
fenofibrate increases plasma levels of the adipocyte-secreted 
anti-inflammatory protein adiponectin, and the increase in 
adiponectin levels were associated with lower levels of the sys-
temic inflammatory mediators VCAM-1, ICAM-1, and CRP. 
Because systemic inflammatory markers are derived from 
multiple sources, it is unclear whether these associations are 
related to circulating mononuclear cells, tissue macrophages, 
or adipocytes. In contrast, the inverse association between adi-
ponectin and reduced LPS-stimulated ex vivo blood cytokine 
production of MCP-1, MIP-1α, and IL-1β suggest more that 
direct involvement of adiponectin and/or adiponectin recep-
tors in circulating leukocytes contribute to the anti-inflamma-
tory effects of fenofibrate. Adiponectin is found in serum an an 
oligomeric trimer of low molecular weight and a hexamer (two 
trimers) of high molecular weight (15). The low molecular 
weight is the predomient isoform in the circulation, whereas 
the high molecular weight constitutes the major component of 
intracellular adiponectin. Although both low molecular weight 
and high molecular weight isoforms of adiponectin activate 
NF-κB (16), it is possible that fenofibrate has different effects 
on the different components of adiponectin that may influence 
the biological activity of increased adiponectin levels; however 
this study only measured total adiponectin levels.
Although activation of PPAR-α has not been considered a 
therapy that would increase adiponectin levels, we are aware 
of two studies that reported an increase in plasma adiponectin 
with fenofibrate therapy (17,18). In a study among 56 patients 
with combined hyperlipidemia (total cholesterol ≥5.17 mmol/l 
and triglycerides ranging from 2.26 mmol/l to 9.03 mmol/l), 
fenofibrate 8 week therapy increased adiponectin levels by 
14% from 3.21 μg/ml to 3.54 μg/ml (P = 0.05) (17). In a second 
adiponectin study, 46 hypertriglyceridemia (≥1.69 mmol/l) 
table 4 Analyses of the associations between adiponectin and inflammatory markers
VCAM-1 ICAM-1 MCP-1 MIP-1α IL-1β CRP Fibrinogen
r P r P r P r P r P r P r P
Model 1 −0.55 <0.0001 −0.56 <0.0001 −0.49 0.0002 −0.42 0.001 −0.45 0.0006 −0.42 0.001 −0.22 0.12
Model 2 −0.54 <0.0001 −0.55 <0.0001 −0.49 0.0002 −0.43 0.001 −0.44 0.001 −0.42 0.002 −0.21 0.14
Model 3 −0.54 <0.0001 −0.57 <0.0001 −0.46 0.001 −0.45 0.001 −0.44 0.002 −0.40 0.004 −0.26 0.078
Model 1 represents univariate Spearman correlations between adiponectin and inflammatory markers. Model 2 represents age- and gender-adjusted Spearman 
correlations between adiponectin and inflammatory markers. Model 3 represents age-, gender-, and weight change–adjusted Spearman correlations between 
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Figure 1 Correlations between adiponectin and inflammatory markers. Inverse association between on-trial adiponectin levels and inflammatory 
markers. Correlations were adjusted for age, gender, and on-trial weight changes. Circles (or squares), placebo group; triangles, fenofibrate group.
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patients, 8 weeks of therapy with fenofibrate increased adi-
ponectin levels by 14 ± 5% (P = 0.008) (18). Among a sub-
set of 24 metabolic syndrome patients with triglycerides 
≥1.7 mmol/l, fenofibrate increased plasma adiponectin lev-
els by 12 ± 6% from 3.35 mg/l to 3.55 mg/l (18). The authors 
suggest that restoration of abnormal endothelial function 
observed in fenofibrate-treated patients may be accompanied 
by improved insulin sensitivity, increased adiponectin expres-
sion and reduced activation of inflammatory pathways (18).
The mechanisms responsible for adiponectin-mediated reduc-
tion of inflammatory cytokine reserve in circulating monocytes 
require further study; however, there are several possible explana-
tions for the anti-inflammatory effects of PPAR-α activation that 
involve NF-κB mediated inflammatory pathways (15,19). Fibrates 
have been shown to induce the expression of the inhibitory pro-
tein IκB in human aortic smooth muscle cells and primary human 
hepatocytes (19). Macrophages contained in visceral fat are a 
rich source of inflammatory cytokines. Activation of PPAR-α by 
fenofibrate would be expected to inhibit NF-κB-mediated TNF-α 
signaling pathways in visceral fat and increase expression of adi-
ponectin. Previously, physiological concentrations of adiponectin 
have been shown to inhibit NF-κB signaling (8) in macrophages 
(9,20) and endothelial cells resulting in reduced expression of 
TNF-α and VCAM-1, ICAM-1, and E-selectin (7); and the pro-
duction of the anti-inflammatory mediators IL-10 and IL-1 recep-
tor antagonist in human leukocytes (21). In visceral fat depots of 
Otsuka Long-Evans Tokushima fatty rats, fenofibrate-reduced 
TNF-α expression and increased adiponectin expression (22). 
Although we did not observe a significant reduction in mono-
nuclear cell TNF-α production, adiponectin mRNA levels have 
been associated with TNF-α mRNA levels (r = −0.48, P < 0.005) 
in adipose tissue of nondiabetes subjects (23).
Recently, two transmembrane proteins that serve as recep-
tors for adiponectin, Adipo R1 and Adipo R2, have been iden-
tified in human atherosclerotic plaques (20). Adipo R1 and 
Adipo R2 are present in monocytes. Expression of these recep-
tors is induced by nuclear receptors for the PPARs α and γ, 
and for liver X receptors (24). Fenofibrate-induced activation 
of PPAR-α would provide more binding sites on mononuclear 
cells for increased circulating adiponectin. Ligation of Adipo1 
and Adipo2 on circulating mononuclear cells has been shown 
to reduce NF-κB activated inflammatory mediators (24). In 
cultured macrophages and experimental animal models, exog-
enous administration of adiponectin counteracts increased 
TNF-α expression. Recombinant adiponectin administration 
has been shown to inhibit LPS-stimulated TNF-α production 
and TNF-α mRNA expression in macrophages (20).
Lifestyle and pharmacological therapies that increase adiponectin 
levels may be valuable in reducing atherosclerotic risk and cardio-
vascular events particularly among individuals with the metabolic 
syndrome and type 2 diabetes. Weight loss is accompanied by an 
increase in adiponectin levels (25). Antidiabetic therapy with thia-
zolidinediones have been shown to increase adiponectin levels in 
nondiabetic subjects and in patients with type 2 diabetes through 
modulation of adiponectin gene expression (26). In patients with 
type 2 diabetes, rosiglitazone (2 mg twice daily) increased mean 
plasma adiponectin levels by more than twofold (P < 0.0005), 
whereas no change was observed in the placebo group. In patients 
with type 2 diabetes, pioglitazone 45 mg daily increased plasma 
adiponectin levels from 6.73 ± 3.42 mg/l to 17.70 ± 8.76 mg/l (P 
< 0.0001), while glimepiride lowered adiponectin levels (6.45 ± 
3. 39 mg/l to 5.96 ± 2.46 mg/l, P < 0.05) (27). In the Rimonabant 
in Obesity–Lipids study, the effects of the selective cannabinoid 
receptor antagonist rimonabant-1 were investigated in overweight 
subjects (BMI 27–40 kg/m2) with untreated dyslipidemia (triglyc-
eride levels >0.73 mmol/l to 3.44 mmol/l, or a ratio of cholesterol 
to HDL-C of >4.5 among women and >5 among men) (28). In 
this study, in which 54% of subjects had the metabolic syndrome, 
rimonabant 20 mg daily increased adiponectin levels by 46.2% (last 
observation carried forward analysis, P < 0.001). Changes in adi-
ponectin levels correlated with changes in HDL-C levels (r = 0.27, P 
< 0.001) and apolipoprotein A-I (r = 0.38, P < 0.001).
The current study explores putative mechanisms for the anti-
inflammatory effects of fenofibrate, and these results cannot be 
extrapolated to cardiovascular outcomes. Further, we included 
obese metabolic syndrome subjects with adiponectin levels that 
were substantially lower than average values reported in the 
Health Professionals Follow-up study. As compared with that 
study, the adiponectin levels in the current study fell within the 
lowest quintile (2.4–10.5 mg/l) of the distribution of the adi-
ponectin levels presumably because our study was limited to 
obese metabolic syndrome patients. Nevertheless, the 0.4 mg/l 
short-term increase in adiponectin levels in fenofibrate-treated 
subjects represents about 20% of the difference in adiponectin 
levels between individuals who experienced an incident myo-
cardial infarction at 6 years vs. those who did not.
In this study, we provide new information regarding the 
effects of fenofibrate on circulating levels of the  adipose- specific 
cytokine adiponectin as well as whole blood production of 
inflammatory chemokines and cytokines, and that these 
changes are inversely correlated. Although the effect of fenofi-
brate on increasing adiponectin levels is significant, these 
changes are rather modest when compared to thiazolidinedi-
ones. The extent of the biological changes and clinical impact 
of fenofibrate-mediated changes in adiponectin are uncer-
tain; however, these data suggest a shared biological pathway 
between visceral adipocyte production of adiponectin and 
mononuclear cell production of inflammatory cytokines.
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